Technology directory
A directory of all technologies currently available for licensing through UCLB.
- By Keyword(s)
- By Reference No.
There are 46 items in the directory (displaying results 1 to 20)
Dengue Virus High-Throughput Fluorescent Assay
We have developed a novel fluorescent assay for the screening of small molecules targeting dengue virus.
| Reference: | 12-001 |
|---|---|
| Availability: | Licenses are available on a non-exclusive basis. We welcome discussions relating to research collaborations |
DDAH1 Small Molecule Antagonists for the Treatment of Sepsis
Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is an enzyme involved in the regulation of nitric oxide (NO) signalling. Researchers at UCL have developed small molecule inhibitors of DDAH1, which may provide novel therapeutics for the treatment of disease states involving excess NO synthesis, including sepsis.
| Reference: | 60-914 |
|---|---|
| Availability: | Licensing and/or co-development |
Mesenchymal Stromal Cells as Therapeutic Vectors for
Scientists at UCL have successfully used bone marrow derived cells to deliver a pro-apoptotic protein as tumour targeted therapy. Mesenchymal stromal cells (MSCs) have been engineered to deliver full-length TNF-related apoptosis-inducing ligand (flTRAIL), a transmembrane protein that causes selective apoptosis of cancer cells. On activation these transduced cells kill cancer cells in vitro, and when systemically delivered they localise to and can eliminate lung metastases.
| Reference: | 60-104 |
|---|---|
| Availability: | licensing and co-development |
Development of a Novel Liver Dialysis Device
Scientists at UCL have developed a novel extracorporal ‘liver support device’ that incorporates albumin removal and replacement and endotoxin removal. Preliminary proof of concept studies of the device in a porcine model of paracetamol-induced acute liver show a clear indication that the animals treated with the device have better clinical outcomes both from the perspective of the physiological variables and also from the survival aspects.
| Reference: | 60-045 |
|---|---|
| Availability: | Licensing and co-development |
Novel UCL Nanocomposite Polymer and its Unique Role in the Field of Biomedical Devices
Our novel nanocomposite polymer (NC) can uniquely achieve complete tissue and blood compatibility, unlike conventional medical polymers such as PTFE and Dacron. This offers exciting possibilities for medical device manufacturers.
| Reference: | 94-092 |
|---|---|
| Availability: | Exclusive and Non-Exclusive licensing |
Neuroprotective Sodium Channel Antagonists – a Novel Treatment for Multiple Sclerosis
Two new series of sodium channel blockers have been identified which also have a protective effect on neuronal cells and tissues. These neuroprotective sodium channel blockers have many potential clinical applications, including treatment of neurodegeneration e.g. glaucoma, multiple sclerosis and Parkinson’s disease pain, and convulsions e.g. in epilepsy.
| Reference: | 92-907 |
|---|---|
| Availability: | Licensing and co-development |
Anti-Scarring Tablet for the Eye
Glaucoma is disease in the eye characterised by the progressive loss of retinal ganglion cells. Elevated intraocular pressure is considered to be the primary cause of optic nerve damage that is typical of the disease. An increase in intraoccular pressure is caused by the increased production of aqueous humour and lack of drainage through the trabecular meshwork. Surgical intervention is often required to reduce intraocular pressure through the insertion of a tube implant. However scarring around the tube is the main cause for the failure of glaucoma filtration surgery.
| Reference: | 88-042 |
|---|---|
| Availability: | Exclusive licensing |
DARC: An Early Stage Diagnostic for Glaucoma, Alzheimer’s and other Neurodegenerative Diseases
DARC: the Diagnosis of Apoptosing Retinal Cells is a new early stage diagnostic method for glaucoma, Alzheimer’s and other neurodegenerative diseases. DARC can also be used as an end point marker for the evaluation of neuroprotective drugs.
| Reference: | 88-024 |
|---|---|
| Availability: | Exclusive licensing |
A New Field of Chemical Reagents:
Maleimides are widely considered the most selective functional group for thiol modification. Fine chemicals companies typically offer more than 50 maleimide-based products, and many more which are manufactured using them. Maleimides react irreversibly with thiols preventing controlled disassembly of conjugates, and they contain a single point of attachment for a functional moiety (such as a fluorophore, biotin, etc).
| Reference: | 23-033 |
|---|---|
| Availability: | Exclusive licensing |
Novel protein fractions induce stem cell proliferation to form bone, blood vessels or neural cells
Summary Stem cells have been induced by novel protein fractions to form osteogenic, angiogenic and neurogenic cells. This discovery has significant implications for tissue regeneration and for treatment of a wide range of medical conditions.
| Reference: | 74-029 |
|---|---|
| Availability: | Available for licensing |
A slow-release cisplatin delivery system for treating cancer
Cisplatin is a widely used and successful anticancer drug. It is a potent antineoplastic but is also very toxic. By incorporating cisplaten into a phosphate-based glass that is biologically degradable, a controlled slow-release mechanism of delivering cisplatin can be achieved.
| Reference: | 74-023 |
|---|---|
| Availability: | licensing |
Mitochondrially-targetted Cyclosporin-A for the Treatment of Heart Attacks & Stroke
We have developed a novel pharmaceutical composition that dramatically reduces tissue damage following heart attacks or stroke. Our patented position specifically targets a previously off-patent pharmaceutical to give a cytoprotective effect. We are currently in early pre-clinical testing, and we welcome negotiations with potential exclusive licensees.
| Reference: | 38-020 (Compound reference: UCLB38020). |
|---|---|
| Availability: | Available for exclusive licensing |
Autoimmunization for the prevention of HIV Infection
We have developed a novel immunopeptide that generates a sustained antibody response that inhibits HIV infection, without causing an autoimmune response. Our composition of matter patent describes a biopharmaceutical technology that inhibits HIV cell entry via blocking of CCR5. This technology was invented by Prof Benny Chain, Head of the Division of Infection & immunity at UCL Our pre-clinical data strongly supports the continuation of the pre-clinical programme we are undertaking, and we plan to enter a Phase 1 study shortly.
| Reference: | 15-021 |
|---|---|
| Availability: | Available for exclusive licensing |
A new Field of Chemical Reagents:
Maleimides are widely considered the most selective functional group for thiol modification. Fine chemicals companies typically offer more than 50 maleimide-based products, and many more which are manufactured using them. Maleimides react irreversibly with thiols preventing controlled disassembly of conjugates, and they contain a single point of attachment for a functional moiety (such as a fluorophore, biotin, etc).
| Reference: | 23-033 |
|---|---|
| Availability: | Available for exclusive/non-exclusive/field-specific licensing |
Rapid Optical Diagnosis of Breast Cancer
This technology is an optical biopsy system based on elastic scattering spectroscopy. No tissue processing is required, and the results are available instantly, needing no expert pathologist interpretation. The equipment is low cost, and there are potential applications in detecting cancer and pre-cancer in a wide range of organs.
| Reference: | 11-004 |
|---|---|
| Availability: | Exclusive & Non-exclusive licensing |
DMACRYS Software - Energy minimisation package to simulate rigid molecules with multipoles
DMACRYS is a software programme to model perfect crystals of rigid polyatomic molecules, allowing lattice energy minimization and calculation of second derivative properties including the elastic tensor and lattice modes.
| Reference: | 23-024 |
|---|---|
| Availability: | Non-Exclusive Licensing |
Model Human skin: A Reproducible, High Throughput and Controllable Synthetic Skin Equivalent
A Novel solution for creating any type of human skin very rapidly (in a matter of minutes rather than weeks/months). The technology can produce identical tissue samples, which could find uses for testing skin products, skin grafts or even cornea generation.
| Reference: | 66-037 |
|---|---|
| Availability: | Licensing or Investment |
Novel Oncology Therapeutic: PKB/AKT Inhibitors
Phosphoinositide (PI) signalling is of utmost importance for cellular function and ultimately human health. Phosphoinositides are important regulators of many signal transduction processes. They control such critical processes as cell growth, communication and differentiation, the understanding of which will ultimately lead to treatments for human diseases such as diabetes or cancer. Phosphorylation and phosphate removal performed by various kinases and phosphatases, respectively, as well as the release of the inositol headgroup by phospholipases are the crucial players that control the flux of inositol lipid metabolism. In particular, the influence of PI 3-kinases for cellular signalling is well documented highlighting the importance of this enzyme in oncology and diabetes. Akt/PKB is a central component of the cell survival pathway and thus has been an important target for oncology drugs
| Reference: | 23-914 |
|---|---|
| Availability: | Further Exemplification – Potential Wellcome Trust Seeding Drug Discovery Award |
A Therapeutic Trial of an Alpha-1 Adrenoceptor Antagonist in Fatty Liver Disease
Non alcoholic fatty liver disease (NAFLD) is now the most common cause of chronic liver disease in developed countries. There is at present no proven therapy for NAFLD. The population prevalence of NAFLD is ~25% with the prevalence of its more severe stage, of fatty liver with inflammation, non alcoholic steatohepatitis (NASH) at ~2.5%. The main therapeutic targets in NASH are arguably fibrogenesis and liver regeneration because in NASH hepatic stellate cells (HSC) – the liver’s principal fibrogenic cells are activated to deposit collagen and other matrix proteins and also because in NASH hepatocyte replication is inhibited secondary to increased oxidant stress. This replicative arrest of hepatocytes in NASH therefore necessitates expansion of the liver’s stem cell compartment to maintain the functional integrity of the liver. An ideal therapy in NASH should therefore be both anti-fibrotic and also expand the liver stem cell compartment to enhance liver repair.
| Reference: | 60-034 |
|---|---|
| Availability: | Further Exemplification – Potential Wellcome Trust Translational Award |
The PSIPRED Protein Structure Prediction Server
The PSIPRED protein structure prediction server allows you to submit a protein sequence, perform a prediction of your choice and receive the results of the prediction via e-mail. You may select one of three prediction methods to apply to your sequence: PSIPRED - a highly accurate method for protein secondary structure prediction, MEMSAT - our widely used transmembrane topology prediction method and GenTHREADER - a sequence profile based fold recognition method.
| Reference: | 30-004 |
|---|---|
| Availability: | Non Exclusive Licensing |
